A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA)

The E-VITA study evaluated the efficacy and tolerability of two schedules of eribulin and lapatinib in patients with trastuzumab-pretreated HER-2-positive metastatic breast cancer. This multicenter, open-label phase II trial, randomly assigned patients with trastuzumab-pretreated HER-2-positive meta...

Full description

Bibliographic Details

Main Authors:	Bischoff, Joachim (Author) , Barinoff, Jana (Author) , Mundhenke, Christoph (Author) , Bauerschlag, Dirk Olaf (Author) , Costa, Serban-Dan (Author) , Herr, Daniel (Author) , Lübbe, Kristina (Author) , Marmé, Frederik (Author) , Maass, Nicolai (Author) , Minckwitz, Gunter von (Author) , Grischke, Eva-Maria (Author) , Müller, Volkmar (Author) , Schmidt, Marcus (Author) , Gerber, Bernd (Author) , Kümmel, Sherko (Author) , Schumacher, Claudia (Author) , Krabisch, Petra (Author) , Seiler, Sabine (Author) , Thill, Marc (Author) , Nekljudova, Valentina (Author) , Loibl, Sibylle (Author)
Format:	Article (Journal)
Language:	English
Published:	APR 2019
In:	Anti-cancer drugs Year: 2019, Volume: 30, Issue: 4, Pages: 394-401
ISSN:	1473-5741
DOI:	10.1097/CAD.0000000000000722
Online Access:	Resolving-System, Volltext: https://dx.doi.org/10.1097/CAD.0000000000000722
Author Notes:	Joachim Bischoff, Jana Barinoff, Christoph Mundhenke, Dirk O. Bauerschlag, Serban-Dan Costa, Daniel Herr, Kristina Luebbe, Frederik Marme, Nicolai Maass, Gunter von Minckwitz, Eva-Maria Grischke, Volkmar Mueller, Marcus Schmidt, Bernd Gerber, Sherko Kuemmel, Claudia Schumacher, Petra Krabisch, Sabine Seiler, Marc Thill, Valentina Nekljudova, Sibylle Loibl